Can a Patient's own immune cells fight tough cancers?

NCT ID NCT05098197

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a treatment called tumor-infiltrating lymphocytes (TILs) in 50 people with advanced liver or pancreatic cancers that have not responded to standard treatments. Doctors take immune cells from a patient's tumor, grow them in a lab, and then infuse them back into the patient after a short course of chemotherapy. The goal is to see if this approach is safe and can shrink tumors or slow cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tumor-infiltrating lymphocytes (TILs)
What this could lead to
If successful, this could point toward a new treatment option for advanced liver and pancreatic cancers that have not responded to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 50 participants, so results may not apply broadly. The treatment involves strong chemotherapy beforehand, which can cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOBILIARY CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai Tenth People's Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.